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INTRODUCTION
Prions are protein-based transmissible pathogens responsi-
ble for fatal neurodegenerative diseases of the central ner-
vous system (CNS), such as Creutzfeldt–Jakob disease (CJD; 
Prusiner, 2013). CJD can be sporadic (sCJD), genetic, iat-
rogenic (iCJD), or zoonotic (such as variant CJD [vCJD]) 
and is uniformly untreatable, presenting a significant public 
health concern. The CJD prion is a misfolded and aggregated 
conformer of the host-encoded prion protein (PrP) that rep-
licates by seeded self-propagating conversion of the host’s 
normal cellular prion protein (PrPC) to the disease-associated 
scrapie form (PrPSc). The genotype at the polymorphic codon 
129 of the human prion protein gene (PRNP), methionine/
methionine (MM), methionine/valine (MV), and valine/va-
line (VV), is critical in determining disease susceptibility and, 
in combination with the conformer of PrPSc present (type 1 
or type 2), defines the disease phenotype. For example, all but 
one of the 178 definite clinical cases of vCJD worldwide have 
occurred in individuals homozygous for methionine at codon 
129 of PRNP (Mok et al., 2017), whereas sCJD occurs in 
all three codon 129 genotypes with distinct phenotypic sub-
types, such as the common MM1 and VV2 subtypes of sCJD 
(Parchi et al., 1999, 2009).
The mechanisms underlying susceptibility, including cell 
type specificity, to infection and the sequence of events that 
lead to neurodegeneration in CJD are poorly understood. Al-
though infectious prions can accumulate in a range of tissues 
and organs expressing PrPC, the pathological effects of prion 
replication appear to be restricted to a progressive neurode-
generative cascade in the CNS, which can be extrapolated 
from animal models of prion diseases (Cunningham et al., 
2003; Gray et al., 2009; Alibhai et al., 2016). Notwithstand-
ing the importance of small and large animal models to our 
understanding of the pathobiology of prion diseases, there 
is an urgent need for complementary experimental systems 
to model aspects of human prion diseases (Jones et al., 2011; 
McCutcheon et al., 2011; Watts and Prusiner, 2014). In this 
regard, cell-free assays have provided important insights into 
prion composition, prion strains, and barriers to prion trans-
mission (Wang et al., 2010; Deleault et al., 2012; Krejciova et 
al., 2014a). Against this background, the availability of a scal-
able and physiologically relevant human-based cellular exper-
imental system to study human prion diseases—including the 
modeling of neuronal–glial interactions that are increasingly 
thought to be involved in neurodegenerative diseases—would 
be of great value (Gómez-Nicola et al., 2013; Asuni et al., 
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2014; Hennessy et al., 2015; Liddelow et al., 2017). However, 
to date, no human cell lines have been described that are di-
rectly and reproducibly susceptible to infection with human 
prions from a CJD brain. The literature contains only one, 
as yet unconfirmed, study of direct sCJD prion infection of 
a human immortalized SH-SY5Y neuroblastoma cell line 
(Ladogana et al., 1995). Consequently, the majority of cell bi-
ology studies of prion replication and its inhibition continue 
to be performed using mouse-adapted prion strains in trans-
formed or transgenic rodent cells (Grassmann et al., 2013). 
Rodent-adapted CJD prions have been shown to replicate in 
an immortalized hypothalamic GT-1 cell line (Arjona et al., 
2004) and rabbit epithelial cell line RK13 expressing mouse 
PrP (Lawson et al., 2008). vCJD and sCJD prions have also 
been shown to replicate in cerebellar granule cells from trans-
genic mice overexpressing human PrP (Cronier et al., 2007; 
Hannaoui et al., 2014). Each of these examples involved the 
passage of human prions through intermediate species and/or 
the use of recipient cells with an experimentally modified 
PRNP genotype, arguably diminishing the relevance of these 
culture models to the study of human prion mechanisms 
of disease. The inadequacy of current cell culture models of 
human prion disease likely contributes to the translational 
failure of apparently promising antiprion compounds from 
the laboratory to clinical practice (Trevitt and Collinge, 2006; 
Stewart et al., 2008; Berry et al., 2013; Watts and Prusiner, 
2014; Giles et al., 2015).
In this study, we establish the first human cell cul-
ture model that can replicate human prions directly from 
CJD-affected brain tissue. We hypothesize that the prereq-
uisites for human prion replication in vitro would include 
matching of agent (inoculum) and host (cell) PrP sequences 
(specifically, the critical M/V polymorphism at codon 129 of 
PRNP) and a relevant differentiated human CNS cell type. 
We tested these requirements for prion infection by exposing 
astrocytes derived from human induced pluripotent stem cells 
(iPSCs) of defined codon 129 genotypes to human prions 
from vCJD and sCJD brains.
RESULTS AND DISCUSSION
Characterization of human iPSC–derived astrocyte 
progenitor cells (APCs) and astrocyte cultures
Astrocytes were generated from iPSC lines using a previ-
ously established protocol (Fig.  1  A; Krencik and Zhang, 
2011; Serio et al., 2013). All iPSC lines used in this study 
have been previously demonstrated to generate functional 
and highly enriched (>90%) astrocyte populations (Krencik 
and Zhang, 2011; Serio et al., 2013; Krencik et al., 2015). 
After PRNP genotyping, two MM (iPSC1 and iPSC4), one 
MV (iPSC2), and one VV (iPSC3) cell line were selected for 
the generation of APCs and astrocytes. Quantitative immu-
nocytochemistry of epidermal growth factor (EGF)/fibro-
blast growth factor (FGF)–treated cultures revealed a highly 
enriched APC-containing population defined by expression 
of APC markers vimentin (iPSC1, 97.1 ± 1.2%; iPSC2, 90 ± 
0.6%; iPSC3, 98.5 ± 0.2%) and nestin (iPSC1, 98.2 ± 2.2%; 
iPSC2, 99.1 ± 0.5%; iPSC3, 98.7 ± 0.3%; Fig. 1 B). After the 
withdrawal of mitogens and addition of ciliary neurotrophic 
factor (CNTF), astrocyte cultures expressing extracellular 
l-glutamate/l-aspartate transporter (GLA ST; Fig.  1 C) and 
GFAP+ (iPSC1, 87.8 ± 1.7%; iPSC2, 91.4 ± 1.7%; iPSC3, 
89.2 ± 0.7%) were generated with comparably low levels of 
other CNS cell markers present, such as NeuN (neurons), 
O4 and Olig2 (oligodendrocytes), and Iba1 and CD68 (mac-
rophages; Fig. 1 D and Fig. S1). Comparable differentiation 
efficiency was observed across all iPSC lines. Immunolabeling 
for the cell proliferation marker Ki67 showed significantly 
reduced proliferation of differentiated astrocyte cultures com-
pared with APC cultures (Fig.  1  E). Functional evaluation 
of iPSC-derived APC and astrocyte cultures confirmed dif-
ferentiation-dependent (astrocyte) functional up-regulation 
of the ability to take up extracellular l-glutamate in a 
time-dependent manner with no differences between lines 
(Fig.  1  F). Having established enriched astrocyte popula-
tions, we next confirmed expression of PrPC across all geno-
types (Fig.  1  G). Immunocytochemistry suggests that PrPC 
resides predominantly on the cell surface, which is consis-
tent with the known localization of PrPC in cultured cells 
(Fig. 1 H; Stahl et al., 1987).
CJD brain samples of different PRNP genotypes 
(Fig.  1  I) used to infect cells were prepared by homogeni-
zation, sonication, and filtration to produce a clarified and 
well-dispersed inoculum with a predefined upper limit to 
particulate size. To determine whether brain homogenate–
derived inocula are toxic to astrocytes, we measured cell 
viability immediately and at 3 d after 24-h exposure of 1% 
vCJD, 1% sCJD, or control normal brain homogenate (NBH) 
inoculum. Cell viability was >95% with no difference be-
tween exposed and unexposed control cells at either time 
point across all genotypes (Fig. 1 J).
Astrocytes are susceptible to direct infection with human 
prions in a PRNP codon 129–dependent manner
Because APC cultures express PrPC, we performed prelimi-
nary experiments to assess the ability of these highly prolif-
erating cells to propagate and accumulate CJD prions after 
24-h exposure to 1% vCJD or sCJD brain homogenates. APC 
cultures were analyzed for PrPSc accumulation at 0, 3, and 8 d 
post exposure (dpe). All APC cultures, regardless of genotype, 
showed a loss of detectable levels of protease-resistant PrPSc in 
cultures up to 8 dpe to vCJD homogenate (Fig. 2, A and B) or 
two different types of genotype-matched sCJD, VV1 or VV2 
(Fig. 2, C and D). This indicated that proliferating precursor 
cells are refractory to prion propagation, which is consistent 
with our previous results (Krejciova et al., 2011).
We next evaluated the capacity of CNTF-differentiated, 
predominantly postmitotic astrocyte cultures to propagate 
human prion strains. MM, MV, or VV genotype astrocytes 
were first tested for their ability to support prion replication 
using vCJD brain homogenate (Fig.  2, E–G). Noting that 
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all vCJD cases with one exception have occurred in MM 
individuals, we hypothesized a greater susceptibility of MM 
astrocytes to vCJD (MM) exposure. Immunoblot analysis 
for protease-resistant PrPSc at 3 and 8 dpe in MM astrocytes 
revealed significant accumulation of PrPSc that substantially 
exceeded the amount of PrPSc in the initial vCJD inoculum, 
as determined by linear regression analysis (Fig. 2 E). In con-
trast, MV and VV astrocytes failed to replicate vCJD (MM) 
prions to detectable levels at the same time points (Fig. 2, F 
and G). To test whether VV astrocytes that failed to replicate 
vCJD (MM) prions were capable of replicating prions with 
a matched genotype, we next exposed VV astrocytes to sCJD 
homogenate derived from a patient homozygous for valine at 
codon 129 (VV2 subtype). Quantitative immunoblot demon-
strated significant PrPSc accumulation at 8 dpe (Fig. 2 H). In 
contrast, no replication was identified after exposure of VV 
astrocytes to an alternate sCJD prion strain from a patient 
with the less common VV1 subtype (Fig. 2 I). These findings 
highlight that specific factors associated with different prion 
strains, as well as genotypes, affect susceptibility to prion rep-
lication. To confirm that the susceptibility of MM astrocytes 
to vCJD prion infection was a function of their genotype and 
not caused by some unknown aspect of the specific iPSC1 
MM cell line used, an additional independent MM astrocyte 
line (iPSC4) was tested, which again demonstrated serial ac-
cumulation of vCJD prions to levels beyond those present in 
the original inoculum (Fig. 2 J).
We next undertook quantitative immunocytochem-
istry to examine cellular accumulation of human prions 
in astrocytes after exposure to CJD prions. Immunocy-
tochemistry was performed using guanidine (Gnd) pre-
treatment, which accentuates PrPSc staining by revealing 
cryptic epitopes buried in aggregated PrPSc. MM astrocytes 
exposed to vCJD (MM) inoculum and VV astrocytes ex-
posed to sCJD (VV2) inoculum showed a significant in-
crease in accumulation of PrPSc at 8 dpe (Fig.  3, A and 
D). In contrast, MV and VV astrocytes did not show an 
increase in PrP immunolabeling after exposure to vCJD 
(MM) inoculum and had a similar appearance to unex-
posed control astrocyte cultures with faint punctate PrPC 
immunolabeling (Fig.  3, B and C). Collectively, these 
data demonstrate that astrocytes are capable of replicat-
ing vCJD and sCJD prions; however, replication of vCJD 
prions over the first 8 d appeared constrained in part by 
the requirement of matching inoculum and cells for the 
PRNP codon 129 genotype.
Dose dependence and subpassage of human 
prions in naive astrocytes
To examine whether the apparent inability of MV and VV 
astrocytes to replicate vCJD prions was dose dependent, cul-
tures of each genotype (MM, MV, and VV) were exposed to a 
range of vCJD inoculum doses from 0.1% to 5%. MM astro-
cytes showed clear dose-dependent replication of vCJD pri-
ons at 3 dpe. However, no evidence of prion replication was 
observed in either MV or VV astrocytes at 3 dpe (Fig. 4 A).
A key feature of prions is the ability to promote rep-
lication of PrPSc upon transmission to an uninfected host. 
To test whether PrPSc produced in human astrocytes was 
able to infect naive astrocyte culture, we next used extracts 
of astrocyte cultures that had previously been exposed to 
CJD brain homogenate and allowed to recover for 8 d as 
inoculum for naive (previously unexposed) astrocyte cul-
tures. Exposure of naive MM astrocytes to vCJD-infected 
(MM) cell inoculum resulted in a substantially increased 
level of PrPSc compared with astrocytes during the first 
passage at 8 dpe (Fig.  4 B). A fourfold increase of PrPSc 
was also observed when VV naive astrocytes were exposed 
to a cell lysate from sCJD (VV2)-infected VV astrocytes 
(Fig. 4, C and D). Immunocytochemistry revealed aggre-
gated PrPSc in infected cells compared with a faint PrPC 
immunostain in unexposed control cells (Fig. 4 E). Both 
subpassage experiments demonstrate that vCJD and sCJD 
prions can be passed from CJD brain homogenate to a 
naive human astrocyte culture and further subpassaged, re-
sulting in increased levels of PrPSc.
Figure 1. Characteristics of iPSC-derived astroglial progenitor cells and astrocytes. (A) Schematic representation of differentiation of healthy donor 
cells to astrocyte progenitors and astrocytes. (B) Representative immunographs and quantification of nestin and vimentin coexpression in APC cultures. 
(C) Representative immunographs of astrocytes of all lines immunostained for GFAP and GLA ST from three replicate experiments. (D) A majority of cells of 
all lines are GFAP-expressing cells (iPSC1, 87.8 ± 1.7%; iPSC2, 91.4 ± 1.7%; and iPSC3, 89.2 ± 0.7%), with a minor proportion expressing the neuronal marker, 
NeuN (iPSC1, 6.3 ± 2%; iPSC2, 5.4 ± 1.8%; and iPSC3, 6 ± 0.4%). (E) Proliferating Ki67-positive cells in iPSC1, iPSC2, and iPSC3 APC and astrocyte cultures. 
(F) Functional evaluation of APC and astrocyte cultures by l-glutamate uptake assay. (G) Representative immunoblots of PrPC expression in MM (iPSC1), MV 
(iPSC2), and VV (iPSC3) lines as APC cultures and their corresponding CNTF differentiated astrocytes from two samples each in two replicate experiments. 
The amount of total protein loaded was 20 µg/lane. The blots were developed with anti-PrP 3F4 antibody and then stripped and reprobed with anti–β actin 
antibody as a loading control. Molecular masses are in kilodaltons. (H) Maximum intensity projection of Z stacks of VV (iPSC3) astrocytes immunolabeled 
for PrPC (green) and cell membrane (white) without and with Triton X-100 permeabilization. (I) Summary table of all cell lines and CJD strain combinations 
with their respective PRNP codon 129 polymorphisms used in this study. (J) Graphic representation of live/dead (viability/cytotoxicity) assay of iPSC1, iPSC2, 
and iPSC3 astrocytes exposed to 1% spin-filtered vCJD, sCJD, or NBHs for 24 h and analyzed immediately (0 dpe) or after 3 d of recovery in fresh media 
(3 dpe). Unexposed cells served as a baseline control for each cell line. Cell count of each group is represented as percentage of total cells, and the data were 
acquired from 10 randomized fields from three replicate experiments, unless otherwise stated. (B–F and J) Data are plotted as mean ± SEM and analyzed by 
one-way ANO VA, followed by Tukey’s multicolumn comparison test; *, P < 0.05; ****, P < 0.0001; ns, not significant. (B, C, and H) Nuclei were stained with 
DAPI (blue). Bars, 20 µm.
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Figure 2. Human iPSC–derived astrocytes replicate PrPSc in vitro in a PRNP codon 129–dependent manner. APC and astrocyte cultures were ana-
lyzed by immunoblots immediately after 24 h of exposure (0 dpe), 3 and 8 dpe. (A) APC cultures of the MM (iPSC1) line exposed to 1% spin-filtered vCJD. APC 
cultures of the VV (iPSC3) line exposed to 1% spin-filtered vCJD (B), sCJD (VV1) (C), and sCJD (VV2) (D). (A–D) n = 1–3, in triplicate. (E) Astrocytes of the MM 
(iPSC1) genotype replicate PrPSc after exposure to 1% spin-filtered vCJD (MM) inoculum. (F) Astrocytes of MV (iPSC2) and (G) VV (iPSC3) genotypes exposed 
to 1% vCJD do not replicate PrPSc. (H) VV (iPSC3) astrocytes replicate PrPSc when exposed to 1% spin-filtered sCJD (VV2) brain homogenate. Representative 
immunoblots and linear regression of PK-resistant PrPSc level from n = 6 (E), n = 4 (F), n = 4 (G), and n = 4 (H) independent identical experiments generally 
performed in triplicate. (I) VV (iPSC3) astrocytes exposed to 1% spin-filtered sCJD (VV1) brain homogenate. (J) Independent MM (iPSC4) astrocytes exposed 
to 1% spin-filtered vCJD (MM). (I and J) n = 1–2, in triplicate. PK-resistant PrPSc signal values in cell lysates were normalized by the PrPSc signal value of the 
inoculum used in each individual experiment. A–D, I, and J are plotted including mean and analyzed by one-way ANO VA followed by Tukey’s multicolumn 
comparison test. (E–H) Mean ± SEM. Linear regression was applied to establish a trend line (black) that is shown with 95% confidence bands (black dotted). 
Dashed gray lines in immunoblot images (E, F, and J) indicate a montage image in which lanes of the same blot and exposure have been rearranged for 
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Differing kinetics of vCJD and sCJD prion propagation in 
long-term astrocyte cultures
The recent identification of a vCJD case in a patient hetero-
zygous at codon 129 of the PRNP (MV) with an extended 
incubation period compared with MM vCJD cases prompted 
us to explore whether the genotypic barriers previously ob-
served in vitro can be overcome in longer-term experiments. 
We first tested MV astrocytes at time points 0, 8, 15, and 28 
dpe to vCJD (MM). Although no PrPSc was evident up to 15 
dpe, immunoblot at 28 dpe revealed PrPSc (Fig. 5 A). These 
findings suggest that heterozygous (MV) astrocytes are able to 
replicate vCJD prions from an MM genotype patient but that 
replication efficiency is very low when compared with vCJD 
(MM) prion replication in MM astrocytes (Fig. 2, E and J). 
We next exposed MM astrocytes to several different strains of 
human CJD prion disease inocula (vCJD MM, sCJD MM1, 
and sCJD VV2) and NBH as a control with assessment of 
PrPSc at time points up to 28 dpe (Fig. 5 B). Progressive accu-
mulation of PrPSc was found in vCJD-treated MM astrocyte 
cultures (Fig. 5 B, lane 1). sCJD MM1 subtype brain homog-
enate displayed lower level PrPSc accumulation (Fig. 5 B, lane 
2). PrPSc was also found in MM astrocyte cultures exposed to 
sCJD (VV2) brain homogenate at 28 dpe (Fig. 5 B, lane 3). 
No PrPSc could be observed in astrocytes exposed to con-
trol NBH (Fig. 5 B, lane 4). To further ascertain the impact 
of genotype on replication susceptibility and efficiency, we 
next exposed VV astrocytes to the sCJD (MM1) strain. VV 
astrocytes showed no detectable accumulation of PrPSc up to 
28 dpe (Fig. 5 C). Finally, we exposed VV astrocytes to vCJD 
(MM), sCJD (VV1), or sCJD (VV2) subtypes for the same 
time periods. Consistent with earlier results, neither vCJD 
(MM) nor sCJD (VV1) prion strains showed detectable PrPSc 
replication in VV cells (Fig. 5 D, lanes 1 and 2); however, a 
very faint PrPSc signal was present at 28 dpe in VV astrocytes 
exposed to vCJD (Fig. 5 D, lane 1). VV astrocytes exposed 
to sCJD (VV2) showed abundant PrPSc accumulation over 
28 d (Fig. 5 D, lane 3). In all cases of positive prion replica-
tion, the proteinase K (PK)–resistant PrPSc pattern showed 
identical mobility and glycoform ratio to those of the brain 
homogenate used for inocula, suggesting that the astrocyte 
cultures propagate strain-associated PrPSc conformers with 
biochemical fidelity (Fig.  2, E, H, and J; Fig.  4, B and C; 
and Fig. 5, A, B, and D).
Human prion replication in human stem 
cell–derived astrocytes
We report the first demonstration of human prion replication 
and prion strain kinetics in a physiologically relevant human 
cellular system. Specifically, we show that human iPSC–de-
rived astrocytes efficiently replicate three distinct human 
prion strains (sCJD [MM1], sCJD [VV2], and vCJD [MM]), 
provided that genotypic barriers to replication and incuba-
tion period are respected. The inability of dividing APCs to 
support prion replication is in agreement with our previous 
study that proliferating undifferentiated human embryonic 
stem cells clear prions to subdetectable levels within 2–3 dpe 
(Krejciova et al., 2011). Our present findings using human 
iPSC–derived astrocytes are therefore consistent with the hy-
pothesis that cellular susceptibility to prion infection is de-
pendent on an appropriate CNS cellular phenotype.
Potential role of astrocytes in prion disease
Although astrocytes have long been known to be pivotal to 
maintaining CNS homeostasis, their role in neurodegenerative 
diseases has come to be appreciated only recently. This is not 
surprising given the intimate structural and functional associ-
ation of astrocytes with, inter alia, the synapse and vasculature 
(Zuchero and Barres, 2015). Although astrocyte pathology is 
well described in prion disease, the role of astrocytes in prion 
pathobiology is unknown (Head et al., 2015). Experimen-
tal evidence from animal and cellular models supports the 
notion that astrocytes may have a role in prion propagation. 
These studies include the finding that PrPSc accumulation in 
astrocytes is an early event in scrapie pathogenesis, preceding 
overt neurodegeneration (Diedrich et al., 1991), as well as the 
observation that experimental scrapie pathology (including 
neuronal death) can occur in transgenic mice in which PrPC 
expression is restricted to astrocytes (Raeber et al., 1997; Jef-
frey et al., 2004; Kercher et al., 2004). These and other studies 
(Victoria et al., 2016) do not, however, distinguish between 
the possibility that astrocytic PrPSc is directly toxic to neu-
rons and/or that PrPSc accumulated by astrocytes adversely 
affects the homeostatic/neuronal support role of astrocytes. 
The findings reported in this study establish an experimental 
platform that permits the study of cell-autonomous and non–
cell autonomous consequences of astrocytic prion replication.
The role of PRNP codon 129 in vCJD prion replication
There have been 178 definite or probable cases of vCJD in the 
UK (1995–2017), and all tested cases have been MM, with the 
exception of a single vCJD case in a heterozygous patient (MV) 
who died in 2016, 16 yr after the first peak of cases in the MM 
genotype (Mok et al., 2017). One interpretation of this obser-
vation is that heterozygosity provides a substantial degree of 
protection from developing clinical vCJD, perhaps effected by 
limiting the rate of vCJD prion replication. Exposure of MM 
astrocyte cultures to vCJD inoculum resulted in a rapid and 
reproducible rise in PrPSc, first detected at 3 dpe, progressively 
continuing to the 28-d stage. In contrast, MV astrocyte cultures 
failed to accumulate detectable PrPSc at early time points, and 
presentation purposes. Note: the y axis in all cells exposed to vCJD (A, B, E–G, and J) has a fivefold-extended range because of high levels of vCJD PrPSc 
accumulation detected in MM (iPSC1 and iPSC4) astrocytes. Blots were developed using anti-PrP 3F4 (A, E, F, and J) and HuM-P (B–D and G–I) antibodies. 
Molecular mass is indicated in kilodaltons. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
 o
n
 N
ovem
ber 21, 2017
jem.rupress.org
D
ow
nloaded from
 
7JEM 
only at 28 dpe was a faint PrPSc signal observed. This implies 
that PRNP codon 129 genotypic effects on vCJD prion rep-
lication can be faithfully modeled in iPSC-derived astrocytes, 
and the results confirm that heterozygosity is an incomplete 
protective factor against vCJD (MM) prion replication in 
human populations, in transgenic modeling, in cellular, and in 
cell-free model systems (Bishop et al., 2006; Jones et al., 2009; 
Mok et al., 2017). Furthermore, we demonstrate that genotype 
is also an important factor in prion replication in sCJD cases, 
whereby genotype-matched patient brain homogenate to the 
cellular genotype was more likely to result in efficient prion 
replication. An exception to this, however, was in the case of 
the sCJD (VV1) subtype, which did not efficiently replicate, 
even in cells of the VV genotype. This suggests that specific 
Figure 3. Human iPSC–derived astrocytes accumulate PrPSc when the CJD inoculum and cell PRNP codon 129 genotype are matched. (A) PrPSc 
accumulation in MM (iPSC1) astrocytes was observed at 8 dpe to 1% spin-filtered vCJD inoculum (bright green). Quantification of PrP immunolabeling 
intensity (right) showed significant increase in cell-associated PrPSc when compared with PrPC of unexposed control cells. (B) MV (iPSC2) astrocytes fail to 
accumulate detectable PrPSc after exposure to 1% spin-filtered vCJD inoculum. Only the faint green immunolabeling of endogenous PrPC can be seen. (C) VV 
(iPSC3) astrocytes fail to accumulate PrPSc when exposed to 1% spin-filtered vCJD. (D) PrPSc accumulation (bright green) in (iPSC3) VV astrocytes exposed to 
1% spin-filtered sCJD (VV2) inoculum and allowed to recover for 8 d. Quantification of PrP immunolabeling intensity (right) showed significant increase in 
cell-associated PrPSc at 8 dpe. Faint green endogenous PrPC signal is present in corresponding unexposed control cells in A–D. The data shown in A–D were 
generated from multiple fields from an experiment conducted in triplicate and are representative of experiments vCJD/iPSC1 (n = 3), vCJD/iPSC2 (n = 2), 
vCJD/iPSC3 (n = 4), and sCJD VV2/iPSC3 (n = 7). PrP signal was normalized by cell count. Data are plotted with mean ± SEM, analyzed by one-way ANO VA, 
and followed by Tukey’s multicolumn comparison test: ****, P < 0.0001; ns, not significant. Cells were immunolabeled with anti-PrP antibody 6H4 (A and B) 
and HuM-P (C and D). Nuclei were stained with DAPI (blue). Bars, 20 µm. ctrl, control.
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aspects of the prion strain itself might also play a substantial 
role in determining prion transmission, which is a comparable 
finding to earlier studies performed using transgenic mice ex-
pressing human PrP (Bishop et al., 2010).
Concluding remarks
To our knowledge, this study that utilizes human iPSC–de-
rived astrocytes is the first to demonstrate that human cells 
of a relevant CNS phenotype are directly susceptible to in-
fection with human prions. Importantly, our cell culture sys-
tem effectively models known aspects of disease susceptibility, 
such as the high susceptibility of the PRNP codon 129 MM 
genotype to vCJD, as compared with the relative resistance 
of the MV or VV genotype. This work therefore represents 
a fundamental advance in modeling human prion disorders 
by establishing a readily scalable system with which to ad-
Figure 4. Dose-dependent accumulation and subpassage of CJD prions in iPSC-derived astrocytes. (A) Immunoblot analysis of astrocytes exposed 
to vCJD (MM) brain homogenate at five concentrations for 24 h and assayed immediately (0 dpe) or after recovery in fresh media for 3 d (3 dpe). MM (iPSC1) 
astrocytes replicate PrPSc in a concentration-dependent manner. MV (iPSC2) and VV (iPSC3) astrocytes failed to replicate PrPSc at 3 dpe. The experiment was 
conducted twice with similar results. (B) MM (iPSC1) astrocytes exposed to 1% spin-filtered vCJD brain homogenate. Both first and second passage were 
analyzed at 8 dpe. In the second passage experiment, the naive MM (iPSC1) astrocytes were exposed to vCJD-infected cell homogenate diluted to match 
PrPSc level of original vCJD brain homogenate used for exposure of astrocytes in the first passage. n = 2, in duplicate. (C) VV (iPSC3) astrocytes exposed 
to 1% spin-filtered sCJD (VV2) brain homogenate (first passage) and sCJD VV2–infected astrocyte homogenate (second passage). The naive VV (iPSC3) 
astrocytes were exposed to a whole sCJD-infected cell homogenate (1:1), i.e., cell lysate of a single well served as an inoculum for a new well because of a 
lower efficiency of sCJD prion propagation. Both passages were analyzed at 8 dpe. n = 2, in triplicate. Blots were developed using anti-PrP (A and B) 3F4 
and (C) HuM-P antibodies. Molecular mass is indicated in kilodaltons. (B and C) Data are plotted with mean. PK-resistant PrPSc signal values in cell lysates 
were normalized by the PrPSc signal value of the inoculum used in each individual experiment. (D) Representative PrP and GFAP immunolabeling in VV 
(iPSC3) astrocytes exposed to 1% spin-filtered sCJD (VV2) brain homogenate (first passage, middle). VV astrocytes exposed to spin-filtered cell homogenate 
of astrocytes propagating sCJD (VV2; second passage, right). Both were analyzed at 8 dpe. PrP immunolabeling intensity (bright green) showed an increase 
in cell-associated PrPSc when astrocytes of first sCJD passage were compared with PrPC of unexposed control cells (control, left), and PrPSc signal appeared 
more abundant in astrocytes in the second passage. n = 2, in triplicate. (E) Maximum intensity projection of Z stacks of VV (iPSC3) astrocytes immunola-
beled for PrP at 8 dpe in cells exposed to sCJD (VV2) infected cell homogenate (right) and unexposed control (left). (D and E) Cells were immunolabeled with 
anti-PrP antibody 3F4. Nuclei were stained with DAPI (blue). Bars: (D) 20 µm; (E) 5 µm.
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Figure 5. Differing kinetics of vCJD and sCJD prion propaga-
tion in human iPSC–derived astrocytes. In all experiments, as-
trocytes were exposed to 1% spin-filtered brain homogenate (24 h) 
and analyzed immediately (0 dpe) and at 8, 15, and 28 d later (8, 15, 
and 28 dpe). (A) Representative immunoblot of MV (iPSC2) astro-
cytes exposed to vCJD brain homogenate. Graphic representation 
of n = 2, duplicate and triplicate. (B) Immunoblots of MM (iPSC1) 
astrocytes exposed to 1% spin-filtered vCJD (lane 1), sCJD (MM1; 
lane 2), sCJD (VV2; lane 3), and NBH (lane 4). (C) Immunoblot of 
VV (iPSC3) astrocytes exposed to sCJD (MM1) brain homogenate. 
Representation of n = 2, in triplicate. (A and C) Data are plotted 
with mean. PK-resistant PrPSc signal values in cell lysates were nor-
malized by the PrPSc signal value of the inoculum used in each indi-
vidual experiment. (D) VV (iPSC3) astrocytes were exposed to vCJD 
(lane 1), sCJD (VV1; lane2), sCJD (VV2; lane 3), and NBH (lane 4). (B 
and D) Blots were developed at the same time/exposure; an exam-
ple of n = 3 is shown. Blots were immunolabeled using anti-PrP 
3F4 (A and B) and HuM-P (C and D) antibodies. Molecular mass is 
indicated in kilodaltons.
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dress mechanistic aspects of human prion infection and to 
facilitate drug discovery.
MATERIALS AND METHODS
Human brain specimens and ethics statement
All human tissues in this study were handled in dedicated 
biosafety level 3* containment facilities according to stringent 
health and safety protocols at the University of Edinburgh and 
the University of California, San Francisco. Brain tissue from 
five cases of autopsy-proven vCJD were used interchangeably 
in this study. All vCJD cases were of UK origin and were 
referred to the National CJD Research & Surveillance Unit 
(NCJ DRSU) for neuropathological diagnosis and surveillance 
purposes. A pathological diagnosis of vCJD had been made 
according to internationally accepted criteria (http ://www . 
cjd .ed .ac .uk /sites /default /files /diagnostic%20criteria .pdf). 
The tissues were sampled from two female and three male 
patients who died at ages ranging from 19 to 53 between 
1996 and 2003. Each was homozygous for methionine (MM) 
at the polymorphic codon 129 of the PRNP gene, and 
mutations in this gene were discounted by gene sequencing. 
Brain tissue from two of the five cases had previously been 
successfully used in experimental animal transmission studies. 
Brain tissue was also used from two cases of autopsy-proven 
sCJD: one of the MM1 subtype, a male who died at age 73 
in 2003, and the other of the VV2 subtype, a male who died 
at age 53 in 1996. Both cases were of UK origin, referred to 
the NCJ DRSU, and diagnosed according to internationally 
accepted criteria. Mutations in the PRNP sequence were 
excluded by gene sequencing. Brain tissue from the sCJD 
VV2 subtype case had previously been successfully used in 
experimental animal transmission studies. Brain tissue from a 
UK individual who had died suddenly of alcohol poisoning 
at age 24 in 2005, without neurological disease, and who was 
found to have no significant neuropathological abnormalities 
at autopsy examination, was used as a negative control for 
prion disease in some experiments reported here. These 
tissues from UK individuals were all provided to this study by 
request from the MRC Edinburgh Brain Bank under ethical 
approval from the East of Scotland Research Ethics Service 
REC 1 (reference number 16/ES/0084), with informed 
consent for research use provided by relatives of the deceased. 
Brain tissue from four further cases of sCJD were provided 
by the University of California, San Francisco Memory and 
Aging Center and were enrolled in the following research 
grants to M. Geschwind: R01AG031189 Early Diagnosis of 
Human Prion Diseases/Predicting Progression of Human 
Prion Diseases and P01AG021601 Novel Therapeutics 
for Prion Diseases. All tissues had consent for research use, 
provided by the relatives of the deceased. These sCJD cases 
comprised one case of the MM1 subtype (a female who died 
at age 66 in 2010), one case of the VV1 subtype (a female who 
died at age 53 in 2011), and two cases of the VV2 subtype (a 
female who died at age 62 in 2007 and a male who died at 
age 75 in 2012). Diagnoses were made in accordance with 
internationally agreed criteria, and mutations in PRNP 
were excluded by gene sequencing. Brain tissue from the 
sCJD VV1 and one VV2 subtype case had previously been 
successfully used in experimental animal transmission studies. 
A further (prion disease negative) control brain used in this 
study, from a 63-yr-old male who died of a heart failure, was a 
gift to S.B. Prusiner (Institute for Neurodegenerative Disease, 
University of California, San Francisco, San Francisco, CA) 
from M. Ingelsson (Uppsala University, Uppsala, Sweden).
PRNP codon 129 genotype
DNA from all iPSC lines was isolated after cell lysis using 
the DNeasy blood and tissue kit (Qiagen). The codon 129 
polymorphism of the PRNP gene (GenBank accession no. 
AL133396) was determined by restriction fragment length 
polymorphism analysis using NspI (New England Biolabs). 
In brief, the 956-bp PRNP gene sequence was PCR am-
plified using forward (5′-TGA TAC CAT TGC TAT GCA CTC 
ATTC-3′) primer and reverse (5′-GAC ACC ACC ACT AAA 
AGG GCT GCAG-3′) primer at 5 pM each per reaction, 
1× NEBuffer 1.1, 0.2  mM deoxynucleoside triphosphate 
(Promega), and 1 U of Taq polymerase (HotStarTaq; Qia-
gen). Restriction enzyme digestion was performed according 
to the manufacturer’s instructions at 37°C. NspI cleaves the 
amplicon once at PRNP codon 155 and a second time at 
codon 129, only when the latter sequence codes for methi-
onine (-ATG-). This enables distinction between the three 
PRNP codon 129 polymorphic genotypes MM, MV, and 
VV by agarose gel electrophoresis and Sybr green staining 
(Thermo Fisher Scientific).
iPSC lines and astrocyte differentiation
Previously generated iPSC-derived astrocyte precursors 
(APCs), shown to produce highly pure and functional astro-
cytes (Krencik and Zhang, 2011; Serio et al., 2013; Krencik et 
al., 2015) were designated iPSC1, iPSC2, and iPSC4 (34D6, 
Lord2R6, and 33D9, respectively; Serio et al., 2013) and 
iPSC3 (162D; Krencik and Zhang, 2011). APCs were grown 
in EGF/FGF-2 (R&D Systems)–containing media at 5 ng/ml 
each, as previously described (Krencik and Zhang, 2011), and 
tested negative for mycoplasma contamination. The protocol 
used for astrocyte differentiation had already been shown to 
yield cells that have astrocyte glutamate transporter func-
tion, and propagate calcium waves via extracellular ATP sig-
naling and the cultures were lacking of neurons (Krencik et 
al., 2011). Moreover, there were no Iba1- or CD68-positive 
(macrophage) cells in the culture Fig. 1 D and Fig. S1). As-
trocytes differentiated using this protocol were shown to ex-
press a full range of astrocyte markers at the quantitative PCR 
and microarray levels and promote formation of synapses 
on human neurons (iPSC3 [162D]; Krencik et al., 2015). 
Astrocyte differentiation was as follows: APCs were disso-
ciated with accutase (Stemcell Technologies), and then cells 
were plated on poly-l-ornithine (PLO; Sigma-Aldrich)– and 
matrigel (BD Matrigel Matrix Growth Factor Reduced; BD 
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Biosciences)-precoated wells. Cells were cultured in neuro-
basal media supplemented with 0.2% B27, 1% nonessential 
amino acids, 1% penicillin and streptomycin, 1% GlutaMax 
(all Gibco), and recombinant human ciliary CNTF (R&D 
Systems) at a final concentration of 10 ng/ml for 2 wk. Astro-
cyte cultures produced by this method were typically >90% 
pure when assessed by immunolabeling for the combina-
tion of astrocytic markers GLA ST (Miltenyi Biotech) and 
GFAP (Millipore) and against the neuronal marker NeuN 
(Abcam), oligodendrocyte markers O4 (R&D Systems) and 
Olig2 (Chemicon), and macrophage markers Iba1 (Abcam) 
and CD68/SR-D1 (Novus).
Glutamate uptake assay
The method used to measure the decrease of glutamate in 
the media over time was adopted (Krencik et al., 2011). In 
brief, cells were plated on matrigel and cultured in EGF/
FGF-2 (APC)– or CNTF (astrocyte; 10 ng/ml each)-con-
taining media for 2 wk. Cells were dissociated with accutase 
and replated at equal density. 4 h after attachment, cells were 
pretreated with high sodium buffer for 30 min to equilibrate 
at 37°C (140 mM NaCl, 4 mM KCl, 2 mM MgCl2, 1 mM 
CaCl2, 23 mM glucose, and 15 mM Hepes, pH 7.4). Cells 
were then treated with high sodium buffer ± 500 µM l-glu-
tamate for 1  h. Media was removed and l-glutamate con-
centration was determined using the glutamine/glutamate 
determination kit (Sigma-Aldrich). HEK293 cells, which do 
not significantly uptake glutamate when compared with dif-
ferentiated astrocytes, were used as a baseline control. After 
subtraction of the blanks (no glutamate added), the decrease 
of glutamate in the media (or uptake by cells) was reported 
as micromolars of glutamate per microgram of protein after 
being normalized to the total protein in each well. The pro-
tein content was determined by a bicinchoninic acid protein 
assay (Pierce). Sample results were within range of a working 
standard curve. Values were normalized to cell numbers at the 
end of the assay. Values are reported as mean ± SEM.
Preparation of CJD inocula
Brain tissue was first homogenized at 10% weight to volume 
(wt/vol) in sterile phosphate buffered saline (PBS)/5% su-
crose at 4°C and then ribolysed for 40 s (MP FastPrep-24). 
The homogenate was then sonicated (Sonicator 3000; Miso-
nix) for 40 s at 80% power output and cleared of particulate 
matter by centrifugation at 424.1 g for 10 s at 4°C. The ho-
mogenate was then filtered by spin filters, pore size 220 nm 
(Agilent Technologies) or pore size 450 nm (Thermo Fisher 
Scientific), at 10,621 g for 15 min at 4°C. Cell homogenate 
inoculum was prepared by scraping astrocytes in Dulbecco’s 
modified PBS (D-PBS) at 8 dpe to CJD brain homogenate. 
Cell homogenates were prepared as follows: astrocytes at 8 
dpe to CJD brain homogenate were washed twice with ice-
cold D-PBS, scraped in D-PBS using silicone cell scraper 
(USA Scientific), and homogenized using a 1-ml syringe with 
a 27-gauge needle, all at 4°C. Next the suspension was cleared 
by centrifugation at 424.1 g for 10 s and spin filtered (pore 
size of 450 nm) at 4°C. Detection of PrPSc in the spin-fil-
tered CJD brain homogenates and cell homogenates was con-
firmed by PK digestion (Novagen) at a final concentration of 
50 µg/ml and immunoblot analysis.
Cell exposure regimen
APCs were plated at a density of 75,000 cells/well in 12-
well plates precoated with PLO and matrigel and maintained 
in EGF/FGF-2–containing medium. Cells were plated at a 
lower density, in comparison to astrocytes, to accommodate 
the highly proliferative nature of APCs. APC cultures intended 
for astrocyte differentiation were plated at a density of 200,000 
cells/well in 12-well plates precoated with PLO and matrigel 
and differentiated for 2 wk in CNTF-containing medium. 
Cells were exposed to vCJD, sCJD, or non-CJD brain homog-
enates (450 nm spin filtered and diluted in culture media) for 
24 h. The medium was then discarded, and cells were washed 
twice with D-PBS at 37°C, given fresh (brain homogenate 
free) CNTF-containing medium, and further cultured. For 
time course studies, exposure was staggered according to the 
desired recovery time, and cultures were then harvested simul-
taneously, thus resulting in cultures of equivalent age in vitro. 
Exposure to human brain homogenate of individuals who died 
of a nonneurological cause (NBH) served as a negative control. 
Cells cultured exclusively in brain homogenate–free CNTF 
medium served as unexposed controls in all experiments. In 
subpassage experiments, naive astrocytes were exposed (24 h) 
to cell homogenate of astrocytes previously exposed to CJD 
brain homogenate and harvested at 8 dpe. Because of the dif-
fering prion replication efficiencies between cells of (MM or 
VV) PRNP polymorphism exposed to different prion strains, 
we chose to normalize the concentration of subpassaged cell 
homogenate (first passage) in two ways. First, lysate dilutions of 
MM (iPSC1) astrocytes exposed to vCJD were quantified for 
levels of PrPSc by immunoblots. The cell homogenate used for 
exposure was diluted to match the amount of PrPSc detected 
in the brain homogenate originally used to infect the astro-
cyte culture. However, in the case of iPSC3 (VV) astrocytes 
exposed to sCJD (VV2), a 1:1 well transmission of cell lysate to 
naive culture was performed instead because of the lower effi-
ciency of sCJD prion replication. For immunocytochemistry 
experiments, APC plated on PLO and matrigel precoated glass 
coverslips (at a density of 50,000 cells/well in 24-well plates) 
were differentiated to astrocytes in CNTF media for 2 wk 
and then exposed to vCJD or sCJD brain homogenates (220 
nm spin filtered and diluted in the CNTF medium) for 24 h. 
The conditions and procedures of each time course were as 
described above. Cultures from each time course experiment 
were terminated and immunolabeled at the same time and 
were therefore at the same culture stage.
Cell viability assay
The cytotoxic effect of the CJD and non-CJD NBH expo-
sure was assessed by the LIVE/DEAD viability/cytotoxicity 
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assay (Thermo Fisher Scientific) according to the manufactur-
er’s instructions. Unexposed cells served as a baseline control. 
Cells were viewed under a differential interference contrast 
microscope (CKX41; Olympus) with reflected fluorescence 
system 494-nm (green) and 528-nm (red) excitation filters. 
Captured images were analyzed using the particle counting 
plugin of ImageJ software (National Institutes of Health).
Anti-PrP antibodies
Immunoblotting for PrP used the mouse monoclonal anti-
body 3F4 obtained from Millipore (MAB1562, human 
PrP epitope 109–112) and the humanized Fab P (HuM-P, 
Prusiner Laboratory, human PrP epitope 96–105; Safar et 
al., 2002). Immunocytochemistry for PrP used the mouse 
monoclonal anti-PrP antibody 6H4 obtained from Prionics 
(01-010) or Thermo Fisher Scientific (7500997; human PrP 
epitope 144–152) and HuM-P. Each antibody recognizes an 
epitope in PrPC that is retained in the protease-resistant core 
of PrPSc, and their specificity has been confirmed (Yull et al., 
2006; Watts et al., 2014).
Immunoblot analysis
Immunoblotting for PrP followed the method of Krejciova 
et al. (2014a,b). In brief, each well was washed twice with 
4°C D-PBS and then lysed on ice for 10 min with radio-
immunoprecipitation assay extraction buffer (Sigma-Aldrich) 
containing protease inhibitors (Complete Mini EDTA-free; 
Roche) and EDTA at 5 mM. The lysate from each well was 
then collected using a silicone cell scraper into safe-lock 
tubes. The samples were digested with PK at a final concen-
tration of 50 µg/ml at 37°C for 60 min, and digestion was 
terminated with 1 mM Pefablock SC (Roche). MgCl2 and 
Benzonase at a final concentration of 1 mM and 50 U/ml, 
respectively, were added to the lysates and incubated at 37°C 
for 10 min before addition of 4× NuPAGE lithium dodecyl 
sulfate sample buffer (Novex) at a final concentration of 1×. 
The entire sample was then boiled at 100°C for 10 min and 
subjected to immunoblot analysis using antiprion protein 
monoclonal antibody 3F4 or HuM-P. The PK digestion step 
was omitted in immunoblotting experiments involving the 
detection of PrPC/β-actin.
Immunocytochemistry
Immunocytochemistry followed the method of Krejciova et 
al. (2014b). In brief, cells were washed twice with D-PBS, 
fixed with 4% paraformaldehyde for 10 min, and permeabi-
lized with 0.1% Triton X-100 for 10 min. A denaturation step 
involving Gnd thiocyanate (+Gnd) pretreatment during the 
immunolabeling procedure was necessary to retrieve PrPSc 
epitopes buried in nondenatured PrPSc aggregates (Giri et 
al., 2006). Cells were pretreated with 4 M Gnd for 10 min 
at room temperature (unless indicated otherwise, −Gnd) and 
blocked with 3% bovine serum albumin for 30 min. The 
cells were then incubated with the primary antibodies PrP 
antibody 6H4, 3F4, or HuM-P, anti-GFAP (Millipore), anti- 
Nestin (Millipore), anti-Vimentin (Abcam), anti-NeuN, an-
ti-Ki67 (Abcam), or anti-GLA ST (Miltenyi Biotech), and 
subsequently the cells were incubated with the secondary 
antibodies Alexa Fluor 488 goat anti–mouse IgG1 anti-
body (Invitrogen) or goat anti–human IgG Fc F(ab′)2 FITC 
(Thermo Fisher Scientific), Alexa Fluor 555 goat anti–rabbit 
IgG (Invitrogen), and Alexa Fluor 647 goat anti–chicken IgG 
(Thermo Fisher Scientific). For plasma membrane staining 
experiments, CellMask (Molecular Probes) was applied to 
fixed cells for 10 min at 37°C before washing in PBS. The 
nuclei were counterstained with DAPI (Invitrogen). Slides 
were mounted with Vectashield (Vector Laboratories Ltd.) 
and examined by confocal microscopy using the LSM 710 
(Zeiss) or TCS SP8 (Leica) microscope. All images from inde-
pendent, but identical, experiments were acquired under the 
same conditions, and laser intensity levels were maintained 
constant throughout to reduce technical variability. Images 
were captured using the Zen 2012 black edition (Zeiss) or 
Las X (Leica) imaging software.
Image quantification and statistical analysis
For quantitative analysis of the cell viability assay, cells were 
counted from each time course over 10 randomly chosen 
areas, and the viable and nonviable cell counts were normal-
ized to corresponding percentages of the cell population and 
plotted as a mean using Prism v.7 software (GraphPad). To 
assess the population of actively proliferating cells in the cul-
ture, APCs and astrocytes were immunolabeled for a cellular 
marker of proliferation, Ki67. DAPI counterstaining was used 
to assess total cell count in each culture. The count of pro-
liferating cells was normalized by total cell count using the 
Prism v.7 software. Data were analyzed from two independent 
experiments (n = 2) in triplicate. Cell culture exposure and 
immunoblot analysis experiments were generally performed 
in triplicate (technical replicates) and repeated (experimental 
n) for each cell line, allowing for quantification and statistical 
analysis. No component parts of the reported experiments 
were excluded for presentational purposes. The numbers of 
independent identical experiments terminated at 8 dpe con-
ducted for each cell line were APC cultures of iPSC1 (n = 2), 
iPSC3 (n = 1) for exposure to vCJD brain homogenate, and 
iPSC3 (n = 2 each) for exposure to sCJD VV1 and VV2. Astro-
cyte exposure was repeated as follows: iPSC1 (n = 6), iPSC2 
(n = 4), iPSC3 (n = 4), iPSC4 (n = 1) for exposures to vCJD 
brain homogenate, and iPSC3 exposed to sCJD VV1 (n = 2) 
and VV2 (n = 4) brain homogenate. For the extended time 
point experiments up to 28 d, iPSC1 cells exposed to vCJD, 
sCJD MM1 or VV2, or a non-CJD brain homogenate (n = 3 
each), iPSC2 astrocytes exposed to vCJD (n = 2), and iPSC3 
exposed to vCJD, sCJD MM1, VV1 or VV2, or a non-CJD 
brain homogenate (n = 2 each). Astrocytes of the iPSC1 (n = 
2) and iPSC3 (n = 2) were used in subpassage experiments. 
Densitometric analysis of the PK-resistant PrPSc bands de-
tected by immunoblot was performed using the volume tool 
of the XRS+ System Image Lab 2.0 software (Bio-Rad). The 
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background signal values of individual blots were subtracted, 
and all samples were normalized against the PK-resistant PrPSc 
signal of the inoculum used in each individual experiment be-
fore data were analyzed and displayed using Prism v.7. Linear 
regression was applied to establish a trend line for the change 
in cell-associated protease-resistant PrPSc over time, which was 
normalized by the protease-resistant PrPSc signal in the inoc-
ulum to which the cell cultures were exposed.
The immunofluorescence data represent analysis of 9–12 
images per time point per independent experiment. Each in-
dependent experiment was performed in triplicate, and the 
numbers of independent identical experiments conducted for 
each cell line were iPSC1 (n = 3), iPSC2 (n = 2), and iPSC3 
(n = 4) for exposures to vCJD brain homogenate and iPSC3 
(n = 7) exposed to sCJD (VV2) brain homogenate. Semiquan-
titative assessment was performed using the ImageJ histogram 
plugin to quantify the intensity of the green fluorescence of 
each image as described previously (Krejciova et al., 2014b). 
The green fluorescence pixel value (corresponding to PrP 
immunolabeling signal) was divided by the cell count of the 
analyzed image (corresponding to DAPI-stained nuclei), thus 
normalizing PrP immunolabeling to cell number. These val-
ues were plotted as arbitrary fluorescence units using Prism 
v.7 software, giving an intensity of PrP immunofluorescence 
per cell. Data were plotted with mean ± SEM and a one-way 
ANO VA followed by Tukey’s multiple comparison test to de-
termine variance compared with the control unexposed cells.
Online supplemental material
Fig. S1 demonstrates the presence of astrocytes after CNTF 
differentiation using the astrocyte marker GFAP and the 
absence of other CNS glial cells using the markers O4 and 
Olig2 for oligodendrocytes and Iba1 and CD68 for microglia.
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